Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator's Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies

Next Previous
Search
Trial Profile

Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator's Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Futuximab/modotuximab (Primary) ; Capecitabine; Fluorouracil
  • Indications Colorectal cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors EMD Serono; Merck KGaA; Symphogen

Most Recent Events

  • 19 Jan 2019 Results establishing a popPK model for Sym004 using data from 4 trials (Sym004-01, Sym004-02, Sym004-05 and Sym004-06) presented at the 2019 Gastrointestinal Cancers Symposium
  • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
  • 12 Sep 2017 Results (n=193) assessing efficacy of futuximab versus best supportive care or capecitabine or 5-fluorouracil in patients with metastatic colorectal cancer and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, were presented at the 42nd European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top